KNSA
Kiniksa Pharmaceuticals Ltd
NASDAQ: KNSA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$52.99
-1.60% today
Updated 2026-04-29
Market cap
$4.08B
P/E ratio
58.23
P/S ratio
6.02x
EPS (TTM)
$0.91
Dividend yield
—
52W range
$25 – $54
Volume
0.8M
Kiniksa Pharmaceuticals Ltd (KNSA) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$52.99
12-Month target
$23.74
2030 Target
—
Intrinsic (DCF)
$202.90
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.2B | $0.3B | $0.4B | $0.7B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 8.71%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.